Arvid Jungnik - Concepedia

Author

Arvid Jungnik

Boehringer Ingelheim (Germany)

Also Known As

A JUNGNIK, A. Jungnik, Arvid Jungnik

Publications

501

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Profil Institute for Metabolic Research

About

Arvid Jungnik is an author at Boehringer Ingelheim (Germany) specializing in pharmacokinetics, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	108
2	Pharmacology	2	2	108
3	Clinical Pharmacology	1	1	48
4	Drug Monitoring	1	1	48
5	Drug Resistance	1	1	60

Arvid Jungnik

Publications

490

Citations

H-Index

Page 1

	Year	Citations
Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen Ping Liu, Hameed Allaudeen, Richa Chandra, Antimicrobial Agents and Chemotherapy	2006	71
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients Patricia N. Sidharta, Fritz Wagner, Holger Bohnemeier, Clinical Pharmacology & Therapeutics	2006	68
Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir Sven Wind, Arvid Jungnik, Tobias Brand, Clinical Drug Investigation Drug InteractionsPharmacokinetic Drug InteractionsPharmacological StudyPharmacologyPharmacotherapy	2014	60
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist <scp>BI</scp> 456906 Arvid Jungnik, Jorge Arrubla, Leona Plum‐Mörschel, Diabetes Obesity and Metabolism	2022	56
Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects Silke Retlich, Vincent Duval, Arne Ring, Clinical Pharmacokinetics Molecular PharmacologyTherapeutic Drug MonitoringPharmacokinetic ModelingPharmacological StudyMedicine	2010	48
Safety, pharmacokinetics and pharmacodynamics of <scp>BI</scp> 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 ( <scp>HSD1</scp> ) inhibitor in humans: liver and adipose tissue 11β‐ <scp>HSD1</scp> inhibition after acute and multiple administrations over 2 weeks S Freude, Tim Heise, Hans J. Woerle, Diabetes Obesity and Metabolism	2016	34
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects Doreen Luedtke, Kristell Marzin, Arvid Jungnik, European Journal of Drug Metabolism and Pharmacokinetics	2018	32
Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail Peter Stopfer, Kathrin Hohl, Ashish Sharma, European Journal of Drug Metabolism and Pharmacokinetics	2017	30
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers Eva U. Graefe-Mody, Arvid Jungnik, Arne Ring, International Journal of Clinical Pharmacology and Therapeutics	2010	28
Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers Linzhi Chen, Arvid Jungnik, Yan‐Ping Mao, Xenobiotica	2014	27

Page 1